<?xml version='1.0' encoding='utf-8'?>
<document id="19841161"><sentence text="No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers."><entity charOffset="39-49" id="DDI-PubMed.19841161.s1.e0" text="lacosamide" /><entity charOffset="54-67" id="DDI-PubMed.19841161.s1.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19841161.s1.e0" e2="DDI-PubMed.19841161.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s1.e0" e2="DDI-PubMed.19841161.s1.e1" /></sentence><sentence text="Lacosamide is a new antiepileptic drug for adjunctive treatment of adult partial-onset seizures"><entity charOffset="0-10" id="DDI-PubMed.19841161.s2.e0" text="Lacosamide" /></sentence><sentence text=" Two open-label, multiple-dose clinical trials were conducted to evaluate the potential for pharmacokinetic interaction between lacosamide and carbamazepine"><entity charOffset="128-138" id="DDI-PubMed.19841161.s3.e0" text="lacosamide" /><entity charOffset="143-156" id="DDI-PubMed.19841161.s3.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19841161.s3.e0" e2="DDI-PubMed.19841161.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s3.e0" e2="DDI-PubMed.19841161.s3.e1" /></sentence><sentence text=" The influence of carbamazepine on lacosamide pharmacokinetics (trial A) and lacosamide on carbamazepine pharmacokinetics (trial B) was investigated in 19 (trial A) and 18 (trial B) healthy male participants"><entity charOffset="18-31" id="DDI-PubMed.19841161.s4.e0" text="carbamazepine" /><entity charOffset="35-45" id="DDI-PubMed.19841161.s4.e1" text="lacosamide" /><entity charOffset="77-87" id="DDI-PubMed.19841161.s4.e2" text="lacosamide" /><entity charOffset="91-104" id="DDI-PubMed.19841161.s4.e3" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e0" e2="DDI-PubMed.19841161.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e0" e2="DDI-PubMed.19841161.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e0" e2="DDI-PubMed.19841161.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e0" e2="DDI-PubMed.19841161.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e1" e2="DDI-PubMed.19841161.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e1" e2="DDI-PubMed.19841161.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e1" e2="DDI-PubMed.19841161.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e2" e2="DDI-PubMed.19841161.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19841161.s4.e2" e2="DDI-PubMed.19841161.s4.e3" /></sentence><sentence text=" Trial A participants received lacosamide 200 mg bid alone and with carbamazepine 200 mg bid"><entity charOffset="31-41" id="DDI-PubMed.19841161.s5.e0" text="lacosamide" /><entity charOffset="68-81" id="DDI-PubMed.19841161.s5.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19841161.s5.e0" e2="DDI-PubMed.19841161.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s5.e0" e2="DDI-PubMed.19841161.s5.e1" /></sentence><sentence text=" Trial B participants received carbamazepine 200 mg bid alone and with lacosamide 200 mg bid"><entity charOffset="31-44" id="DDI-PubMed.19841161.s6.e0" text="carbamazepine" /><entity charOffset="71-81" id="DDI-PubMed.19841161.s6.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.19841161.s6.e0" e2="DDI-PubMed.19841161.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s6.e0" e2="DDI-PubMed.19841161.s6.e1" /></sentence><sentence text=" Pharmacokinetic parameters, area under the concentration-time curve during a dosage interval at steady state (AUC(tau,ss)), and maximum steady-state plasma drug concentration during a dosage interval (C(max,ss)) of lacosamide, carbamazepine, and carbamazepine-10,11-epoxide were measured and compared for each drug alone and together"><entity charOffset="216-226" id="DDI-PubMed.19841161.s7.e0" text="lacosamide" /><entity charOffset="228-241" id="DDI-PubMed.19841161.s7.e1" text="carbamazepine" /><entity charOffset="247-274" id="DDI-PubMed.19841161.s7.e2" text="carbamazepine-10,11-epoxide" /><pair ddi="false" e1="DDI-PubMed.19841161.s7.e0" e2="DDI-PubMed.19841161.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s7.e0" e2="DDI-PubMed.19841161.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19841161.s7.e0" e2="DDI-PubMed.19841161.s7.e2" /><pair ddi="false" e1="DDI-PubMed.19841161.s7.e1" e2="DDI-PubMed.19841161.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19841161.s7.e1" e2="DDI-PubMed.19841161.s7.e2" /></sentence><sentence text=" The AUC(tau,ss) and C(max,ss) point estimates (combined vs sole treatment) showed relative bioavailability of approximately 100% for both drugs" /><sentence text=" All 90% confidence intervals of AUC(tau,ss) and C(max,ss) were within the generally accepted bioequivalence ranges of 80% to 125%" /><sentence text=" No changes in rate or extent of absorption or terminal half-life were observed" /><sentence text=" These results suggest that lacosamide and carbamazepine have a low potential for pharmacokinetic drug-drug interaction in clinical use"><entity charOffset="28-38" id="DDI-PubMed.19841161.s11.e0" text="lacosamide" /><entity charOffset="43-56" id="DDI-PubMed.19841161.s11.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19841161.s11.e0" e2="DDI-PubMed.19841161.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19841161.s11.e0" e2="DDI-PubMed.19841161.s11.e1" /></sentence><sentence text="" /></document>